Newer therapeutic options for children with diabetes mellitus

Theoretical and practical considerations

George S. Jeha, Rubina A. Heptulla

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Recent studies in adult patients with type 1 diabetes mellitus (T1DM) and T2DM have examined the potential utility, benefits, and side effects of agents that augment insulin secretion after oral ingestion of nutrients in comparison with intravenous nutrient delivery, the so-called incretins. Two families of incretin-like substances are now approved for use in adults. Glucagon-like peptide-1 (GLP-1) or agents that bind to its receptor (exenatide, Byetta ®) or agents that inhibit its destruction [dipeptidy] peptidase-IV (DPP-IV) inhibitors, Vildagliptin] improve insulin secretion, delay gastric emptying, and suppress glucagon secretion while decreasing food intake without increasing hypoglycemia. Pramlintide, a synthetic amylin analog, also decreases glucagon secretion and delays astric emptying, improves hemoglobin A1c (HbA1C), and facilitates weight reduction without causing hypoglycemia. We review the historical discovery of these agents, their physiology applications, and their current applications. Remarkably, only one or two studies have been reported in children. Pediatricians caring for children with T1DM and T2DM should become familiar with these agents and investigate their applicability, as they seem likely to enhance our therapeutic armamentarium to treat children with diabetes mellitus.

Original languageEnglish (US)
Pages (from-to)122-138
Number of pages17
JournalPediatric Diabetes
Volume7
Issue number2
DOIs
StatePublished - May 2006
Externally publishedYes

Fingerprint

Incretins
Diabetes Mellitus
Glucagon
Type 1 Diabetes Mellitus
Hypoglycemia
Eating
Insulin
Islet Amyloid Polypeptide
Food
Glucagon-Like Peptide 1
Gastric Emptying
Protease Inhibitors
Weight Loss
Hemoglobins
Therapeutics
exenatide
pramlintide
vildagliptin
Pediatricians

Keywords

  • Amylin
  • Dipeptidyl peptidase-IV
  • Exenatide
  • Exendin 4
  • Gastric emptying
  • Glucagon-like peptide-l
  • Hyperglycemia
  • Hypoglycemia
  • Incretins
  • Liraglutide
  • Pramlintide
  • Type 1 diabetes mellitus-type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism

Cite this

Newer therapeutic options for children with diabetes mellitus : Theoretical and practical considerations. / Jeha, George S.; Heptulla, Rubina A.

In: Pediatric Diabetes, Vol. 7, No. 2, 05.2006, p. 122-138.

Research output: Contribution to journalArticle

Jeha, George S. ; Heptulla, Rubina A. / Newer therapeutic options for children with diabetes mellitus : Theoretical and practical considerations. In: Pediatric Diabetes. 2006 ; Vol. 7, No. 2. pp. 122-138.
@article{51eae272f9e2445190a5d0b47a3ccb3c,
title = "Newer therapeutic options for children with diabetes mellitus: Theoretical and practical considerations",
abstract = "Recent studies in adult patients with type 1 diabetes mellitus (T1DM) and T2DM have examined the potential utility, benefits, and side effects of agents that augment insulin secretion after oral ingestion of nutrients in comparison with intravenous nutrient delivery, the so-called incretins. Two families of incretin-like substances are now approved for use in adults. Glucagon-like peptide-1 (GLP-1) or agents that bind to its receptor (exenatide, Byetta {\circledR}) or agents that inhibit its destruction [dipeptidy] peptidase-IV (DPP-IV) inhibitors, Vildagliptin] improve insulin secretion, delay gastric emptying, and suppress glucagon secretion while decreasing food intake without increasing hypoglycemia. Pramlintide, a synthetic amylin analog, also decreases glucagon secretion and delays astric emptying, improves hemoglobin A1c (HbA1C), and facilitates weight reduction without causing hypoglycemia. We review the historical discovery of these agents, their physiology applications, and their current applications. Remarkably, only one or two studies have been reported in children. Pediatricians caring for children with T1DM and T2DM should become familiar with these agents and investigate their applicability, as they seem likely to enhance our therapeutic armamentarium to treat children with diabetes mellitus.",
keywords = "Amylin, Dipeptidyl peptidase-IV, Exenatide, Exendin 4, Gastric emptying, Glucagon-like peptide-l, Hyperglycemia, Hypoglycemia, Incretins, Liraglutide, Pramlintide, Type 1 diabetes mellitus-type 2 diabetes mellitus",
author = "Jeha, {George S.} and Heptulla, {Rubina A.}",
year = "2006",
month = "5",
doi = "10.1111/j.1399-543X.2006.00159.x",
language = "English (US)",
volume = "7",
pages = "122--138",
journal = "Pediatric Diabetes",
issn = "1399-543X",
publisher = "Blackwell Munksgaard",
number = "2",

}

TY - JOUR

T1 - Newer therapeutic options for children with diabetes mellitus

T2 - Theoretical and practical considerations

AU - Jeha, George S.

AU - Heptulla, Rubina A.

PY - 2006/5

Y1 - 2006/5

N2 - Recent studies in adult patients with type 1 diabetes mellitus (T1DM) and T2DM have examined the potential utility, benefits, and side effects of agents that augment insulin secretion after oral ingestion of nutrients in comparison with intravenous nutrient delivery, the so-called incretins. Two families of incretin-like substances are now approved for use in adults. Glucagon-like peptide-1 (GLP-1) or agents that bind to its receptor (exenatide, Byetta ®) or agents that inhibit its destruction [dipeptidy] peptidase-IV (DPP-IV) inhibitors, Vildagliptin] improve insulin secretion, delay gastric emptying, and suppress glucagon secretion while decreasing food intake without increasing hypoglycemia. Pramlintide, a synthetic amylin analog, also decreases glucagon secretion and delays astric emptying, improves hemoglobin A1c (HbA1C), and facilitates weight reduction without causing hypoglycemia. We review the historical discovery of these agents, their physiology applications, and their current applications. Remarkably, only one or two studies have been reported in children. Pediatricians caring for children with T1DM and T2DM should become familiar with these agents and investigate their applicability, as they seem likely to enhance our therapeutic armamentarium to treat children with diabetes mellitus.

AB - Recent studies in adult patients with type 1 diabetes mellitus (T1DM) and T2DM have examined the potential utility, benefits, and side effects of agents that augment insulin secretion after oral ingestion of nutrients in comparison with intravenous nutrient delivery, the so-called incretins. Two families of incretin-like substances are now approved for use in adults. Glucagon-like peptide-1 (GLP-1) or agents that bind to its receptor (exenatide, Byetta ®) or agents that inhibit its destruction [dipeptidy] peptidase-IV (DPP-IV) inhibitors, Vildagliptin] improve insulin secretion, delay gastric emptying, and suppress glucagon secretion while decreasing food intake without increasing hypoglycemia. Pramlintide, a synthetic amylin analog, also decreases glucagon secretion and delays astric emptying, improves hemoglobin A1c (HbA1C), and facilitates weight reduction without causing hypoglycemia. We review the historical discovery of these agents, their physiology applications, and their current applications. Remarkably, only one or two studies have been reported in children. Pediatricians caring for children with T1DM and T2DM should become familiar with these agents and investigate their applicability, as they seem likely to enhance our therapeutic armamentarium to treat children with diabetes mellitus.

KW - Amylin

KW - Dipeptidyl peptidase-IV

KW - Exenatide

KW - Exendin 4

KW - Gastric emptying

KW - Glucagon-like peptide-l

KW - Hyperglycemia

KW - Hypoglycemia

KW - Incretins

KW - Liraglutide

KW - Pramlintide

KW - Type 1 diabetes mellitus-type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=33645804036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645804036&partnerID=8YFLogxK

U2 - 10.1111/j.1399-543X.2006.00159.x

DO - 10.1111/j.1399-543X.2006.00159.x

M3 - Article

VL - 7

SP - 122

EP - 138

JO - Pediatric Diabetes

JF - Pediatric Diabetes

SN - 1399-543X

IS - 2

ER -